D. E. Shaw & Co., Inc. Gemini Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 16, 2022	SELL	$1.29 - $3.08 $24,862 - $59,360	-19,273 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.39 - $4.0 $46,062 - $77,092	19,273 New	19,273 $56,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.